



شبكة المعلومات الجامعية

بسم الله الرحمن الرحيم



شبكة المعلومات الجامعية
@ ASUNET



شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



شبكة المعلومات الجامعية

جامعة عين شمس

التوثيق الالكتروني والميكرو فيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأفلام قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأفلام بعيدا عن الغبار

في درجة حرارة من ١٥-٢٥ مئوية ورطوبة نسبية من ٢٠-٤٠%

To be Kept away from Dust in Dry Cool place of
15-25- c and relative humidity 20-40%

بعض الوثائق الأصلية تالفة

بالرسالة صفحات لم ترد بالاصل

61829201

٢٤١٢
٢٠

Minoufya University
Faculty of medicine

A Randomized Trial
Of
Recombinant Human Granulocytes Colony Stimulating
Factor, (G-CSF) and Intravenous Immunoglobulin (IVIG)
Administration in Newborn Infants with Late Onset
Sepsis
Thesis

Submitted for partial fulfillment of
M.D degree in Pediatrics

By

Mohamed Fawzy Al-soda

(M.B.B.Ch., M.SC)

Supervised by

Prof. Dr.

Mamdouh Y.M. Refaat

Professor and chairman of
Pediatrics Department

Minoufiya Faculty of Medicine

Prof. Dr.

Laila Montaser

Professor of
Clinical Pathology

Minoufiya Faculty of Medicine

Prof. DR.

Mohamed Bahbah

Assist. Professor of Pediatrics
Minoufiya Faculty of Medicine

Prof. Dr

Fady Al-Gendy

Assist. Professor of Pediatrics
Minoufiya Faculty of Medicine

8/2003

FADJ

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

((قَالَ لَوْ لَا سُبْحَانَكَ اللَّهُ عَمَّا يُشْرِكُونَ اللَّهُمَّ إِنَّا جَاءْنَاكَ عِبَادًا وَنَسْتَغْفِرُكَ وَلَمَّا جَاءْنَاكَ عِبَادًا وَنَسْتَغْفِرُكَ وَلَمَّا جَاءْنَاكَ عِبَادًا وَنَسْتَغْفِرُكَ))

((إِنِّي أَنَا اللَّهُ الْعَلِيُّ الْعَلِيمُ))

صدق الله العظيم

"سورة البقرة آية ٣٣"

Acknowledgment

I would like to express my sincere gratitude and my deep appreciation to **Prof. Dr. Mamdouh Refaat Professor and Chairman of Pediatric Department**, Faculty of Medicine Minoufiya University, for his valuable supervision, help and continuous encouragement.

I wish to acknowledge the sincere care and valuable guidance of **Prof. Dr. Laila Montaser Professor of Clinical Pathology**, Faculty of Medicine Minoufiya University, to whom I am really indebted for her valuable supervision and for taking the burden of the practical part of this work.

I wish also to express my gratitude and appreciation to **Prof. Dr. Mohamed Bahbah Assistant Professor of Pediatric**, Faculty of Medicine Minoufiya University, for his kind supervision, valuable advice and generous support throughout the course of this work.

A special effort was generously offered by **Prof. Dr. Fady Al-Gendy Assistant Professor of Pediatric**, Faculty of Medicine Minoufiya University. I am so grateful to his valuable supervision.

Finally, I would like to thank **Dr. Nagwa Gad, Lecturer of Pediatrics**, Faculty of Medicine Minoufiya University for her continuous efforts which helped to fulfill this work.

Mohamed Fawzy Al-Soda

Minfoufiya 2003

Contents

Content	Page
<i>Tables index</i>	III
<i>Appendices index</i>	V
<i>Abbreviations</i>	VI
<i>Introduction and aim of the work</i>	1
<i>Review of literature</i>	5-108
Neonatal sepsis	5
Immunotherapy for neonatal sepsis	64
Intravenous Immunoglobulins (IVIG)	77
Granulocytes colony stimulating factor (G-CSF)	88
<i>Subjects and methods</i>	109
<i>Results</i>	117
<i>Discussion</i>	142
<i>Summary and conclusion</i>	155
<i>Recommendations</i>	158
<i>References</i>	159
<i>Appendices</i>	201
<i>Arabic summary</i>	

Tables index

Table	Title	Page
(1)	The sex of the different study groups patients.	117
(2)	The mode of delivery of the different study groups.	117
(3)	The gestational age of different study group patients.	118
(4)	Birth weight (gm) of the different study groups.	118
(5)	Clinical score of the different study groups.	119
(6)	Hematological score of the different study groups.	119
(7)	Onset of sepsis (days) of the different study groups.	120
(8)	Clinical presentations and its percentage in study populations.	121
(9)	Primary diagnosis of different study populations.	122
(10)	The causative organism and its percentage of different study groups	123
(11)	The mean total leukocytic count and absolute neutrophilic count (meta-and pro-myelocytes are not included) of different study group at time of diagnosis.	124
(12)	The difference between mean total leukocytic count of group A patients at time of diagnosis and after 24, 48, 72 hours of treatment.	125
(13)	The difference between mean total leukocytic count of group B patients at time of diagnosis and after 24, 48, 72 hours of treatment.	126
(14)	The difference between mean total leukocytic count of group C patients at time of diagnosis and after 24, 48, 72 hours of treatment.	127
(15)	Differences between mean total leukocytic count of different study group after 24, 48, 72 hours of treatment	128
(16)	The difference between mean absolute neutrophilic count of group A patients at time of diagnosis and after 24, 48, 72 hours of treatment.	130
(17)	The difference between mean absolute neutrophilic count of group B patients at time of diagnosis and after 24, 48, 72 hours of treatment	131
(18)	The difference between mean absolute neutrophilic count of group C patients at time of diagnosis and after 24, 48, 72 hours of treatment.	132

Table	Title	Page
(19)	Mean absolute neutrophilic count at time of diagnosis and difference between each different two study groups after 24, 48, 72 hours of treatment.	133
(20)	The difference between the mean serum G-CSF concentration (pg/ml) for the three different study groups at time of diagnosis and after 24 hours of treatment	135
(21)	The difference between mean serum G-CSF concentration (pg/ml) for of the different study groups at diagnosis and after 24 hours of treatment.	136
(22)	Duration of hospital stay (days) of the study groups.	137
(23)	Duration of antibiotic therapy (days) of the study groups.	137
(24)	Number of antibiotic used in the study groups.	138
(25)	The difference between incidences of complications of different study groups.	138
(26)	Acute complications for the study groups.	139
(27)	The rate of survival of different study groups.	140
(28)	The difference between survivors and non-survivors regarding birth weight, gestational age, hospital stay, number of antibiotic used.	141

Appendices

Appendix	Title	Page
(1)	Demographic characteristics of group A patients	201
(2)	Demographic characteristics of group B patients	202
(3)	Demographic characteristics of group C patients	203
(4)	Total leukocytic counts and absolute neutrophilic count for group A patients at time of diagnosis	204
(5)	Total leukocytic counts and absolute neutrophilic count for group B patients at time of diagnosis	205
(6)	Total leukocytic counts and absolute neutrophilic count for group C patients at time of diagnosis	206
(7)	Total leukocytic counts of group A patients (control):	207
(8)	Total leukocytic counts after G-CSF treatment of group B patients	208
(9)	Total leukocytic counts after G-CSF and IVIG treatment of group C patients	209
(10)	Absolute neutrophilic count and percentage of group A patients (control)	210
(11)	Absolute neutrophilic count and percentage after G-CSF treatment of group B patients	211
(12)	Absolute neutrophilic count and percentage after G-CSF and IVIG treatment of group C patients	212
(13)	Serum G-CSF for patients of group A	213
(14)	Serum G-CSF concentration before and 24 hours after G-CSF treatment in patients of group B	214
(15)	Serum G-CSF concentration before and 24 hours after G-CSF and IVIG treatment in patients of group C	215